Salicylic acid

US Approved OTC

First marketed in 1860

Details

Stereochemistry	ACHIRAL
Molecular Formula	C7H6O3
Molecular Weight	138.1207
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=C(O)C=CC=C1

InChI

InChIKey=YGSDEFSMJLZEOE-UHFFFAOYSA-N

InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)

HIDE SMILES / InChI

Molecular Formula	C7H6O3
Molecular Weight	138.1207
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

Methyl salicylate (or methyl 2-hydroxybenzoate), also known as wintergreen oil, is a natural product and is present in white wine, tea, porcini mushroom Boletus edulis, Bourbon vanilla, clary sage, red sage and fruits including cherry, apple, raspberry, papaya and plum. Methyl salicylate is topically used in combination with methanol and under brand name SALONPAS to temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises. The precise mechanism of action of methyl salicylate is not known, but there is suggested, that it cause dilation of the capillaries thereby increasing blood flow to the area.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cyclooxygenase-1 127 Target ID: CHEMBL221 Sources: http://www.drugbank.ca/drugs/DB00936	Inhibitor 8297
Cyclooxygenase-2 196 Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00936	Inhibitor 8297
High mobility group protein B1 13 Target ID: CHEMBL2311236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26101955	Inhibitor 8297	1.48 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Strains and sprains 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf	Palliative	Approved 8429	SALONPAS Approved Use Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date 2008
Simple backache 18 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf	Palliative	Approved 8429	SALONPAS Approved Use Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date 2008
Arthritis 89 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf	Palliative	Approved 8429	SALONPAS Approved Use Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date 2008
Bruises 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf	Palliative	Approved 8429	SALONPAS Approved Use Temporarily relieves mild to moderate aches and pains of muscles and joints associated with: strains, sprains, simple backache, arthritis, bruises Launch Date 2008
Psoriasis 84 Sources: https://www.drugs.com/pro/salicylic-acid.html	Primary	Approved 8429	Salicylic Acid Approved Use Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date 2012
Keratosis palmaris 12 Sources: https://www.drugs.com/pro/salicylic-acid.html	Primary	Approved 8429	Salicylic Acid Approved Use Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date 2012
Ichthyosis vulgaris 12 Sources: https://www.drugs.com/pro/salicylic-acid.html	Primary	Approved 8429	Salicylic Acid Approved Use Salicylic Acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). Launch Date 2012

T_1/2

Value	Dose	Co-administered	Analyte	Population
238 min EXPERIMENT https://www.sciencedirect.com/science/article/abs/pii/S0022354915364558	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:		SALICYLIC ACID plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/	unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/	Other AEs: Redness, Scales... Other AEs: Redness Scales Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/

AEs

AE	Significance	Dose	Population
Redness		30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/	unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/
Scales		30 % 1 times / 2 weeks multiple, topical Dose: 30 %, 1 times / 2 weeks Route: topical Route: multiple Dose: 30 %, 1 times / 2 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/	unhealthy, 23.05 ± 5.7 years n = 43 Health Status: unhealthy Condition: Acne vulgaris Age Group: 23.05 ± 5.7 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/27904577/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2C8 693 CYP2C19 991 CYP2E1 667 CYP2A6 543 CYP2B6 664 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213	CYP2E1 128

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2E1 970	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/9207195/	yes

Drug as victim

Target	Modality	Activity
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	likely
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	likely
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	major
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	no
UGT2B15 203	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	no
UGT2B17 213	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	no
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	yes
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	yes
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	yes
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	yes
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/25840124/	yes
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A10 291	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A7 236	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A8 283	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16258079/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:16914	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16914
ChemicalBook	CB1680010	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1680010
MolPort	MolPort-001-769-476	https://www.molport.com/shop/molecule-link/MolPort-001-769-476
ZINC	ZINC000000001554	http://zinc15.docking.org/substances/ZINC000000001554
eMolecules	478035	https://www.emolecules.com/cgi-bin/more?vid=478035

PubMed

Title	Date	PubMed
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.	2001	11314772
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries.	2001	11296921
The solvent shells of cluster ions produced by direct electric field extraction from glycerol/water mixtures.	2001	11268133
Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.	2001 Apr	11328677
Cyanide-resistant alternative respiration is strictly correlated to intracellular peroxide levels in Acremonium chrysogenum.	2001 Apr	11328676
[Principal constituents from flowering aerial parts of wild pansy].	2001 Apr	11320336
A novel jasmonic acid-inducible rice myb gene associates with fungal infection and host cell death.	2001 Apr	11310740
Abnormal callose response phenotype and hypersusceptibility to Peronospoara parasitica in defence-compromised arabidopsis nim1-1 and salicylate hydroxylase-expressing plants.	2001 Apr	11310731
Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane.	2001 Apr	11305600
Nucleotide sequence analysis of 5'-flanking region of salicylate hydroxylase gene, and identification and purification of a LysR-type regulator, SalR.	2001 Apr	11298739
Nitric oxide: comparative synthesis and signaling in animal and plant cells.	2001 Apr	11286923
Sodium salicylate increases CYP2E1 levels and enhances arachidonic acid toxicity in HepG2 cells and cultured rat hepatocytes.	2001 Apr	11259624
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).	2001 Apr 13	11334847
Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease.	2001 Apr 17	11303744
Effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on nitric oxide-induced hydroxyl radical generation in the rat heart.	2001 Apr 30	11335104
[Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].	2001 Apr 6	11332239
Hereditary palmoplantar keratoderma (four cases in three generations).	2001 Feb	11328395
Induction of wound response gene expression in tomato leaves by ionophores.	2001 Feb	11289608
Isolation and preliminary characterization of the medium-chain fatty acid:CoA ligase responsible for activation of short- and medium-chain fatty acids in colonic mucosa from swine.	2001 Feb	11281196
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs.	2001 Feb	11272320
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.	2001 Feb	11266322
Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis.	2001 Feb	11259991
Increased leukotriene production by food additives in patients with atopic dermatitis and proven food intolerance.	2001 Feb	11251628
A hot pepper cDNA encoding a pathogenesis-related protein 4 is induced during the resistance response to tobacco mosaic virus.	2001 Feb 28	11266114
Molecular cloning of the nahG gene encoding salicylate hydroxylase from Pseudomonas fluorescens.	2001 Feb 28	11266111
Characterization of PBZ1, a probenazole-inducible gene, in suspension-cultured rice cells.	2001 Jan	11272832
Pathogen-induced expression of plant ATP: citrate lyase.	2001 Jan 19	11271173
Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.	2001 Jan-Feb	11299731
Interaction of the Arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3.	2001 Jul 13	11335717
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus.	2001 Jul 6	11306574
Selective suppression of CCAAT/enhancer-binding protein beta binding and cyclooxygenase-2 promoter activity by sodium salicylate in quiescent human fibroblasts.	2001 Jun 1	11278846
A recessive mutation in the Arabidopsis SSI2 gene confers SA- and NPR1-independent expression of PR genes and resistance against bacterial and oomycete pathogens.	2001 Mar	11309146
Signaling mediated by the closely related mammalian Rho family GTPases TC10 and Cdc42 suggests distinct functional pathways.	2001 Mar	11306516
The Arabidopsis downy mildew resistance gene, RPP13-Nd, functions independently of NDR1 and EDS1 and does not require the accumulation of salicylic acid.	2001 Mar	11277440
Development of QSARs to investigate the bacterial toxicity and biotransformation potential of aromatic heterocylic compounds.	2001 Mar	11272910
Interference by bilirubin in salicylate measurement.	2001 Mar	11269759
Effect of lipophilicity on in vivo iontophoretic delivery. I. NSAIDs.	2001 Mar	11256485
Identification of free radicals produced during phacoemulsification.	2001 Mar	11255062
Flow-through UV spectrophotometric sensor for determination of (acetyl)salicylic acid in pharmaceutical preparations.	2001 Mar 23	11274811
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes.	2001 Mar 23	11274806
Microdialysis of salicylic acid from viscous emulsion samples prior to high-performance liquid chromatographic determination.	2001 Mar 30	11307985
Determination of salicylate, gentisic acid and salicyluric acid in human urine by capillary electrophoresis with laser-induced fluorescence detection.	2001 Mar 5	11254191
Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.	2001 May	11335071
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals.	2001 May	11329530
Acanthoamoeba attachment to contact lenses.	2001 May	11320007
Anti-inflammatory and antipyretic effects of Trigonella foenum-graecum leaves extract in the rat.	2001 May	11297864
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.	2001 May	11288110
Measurement of free radical production by in vivo microdialysis during ischemia/reperfusion injury to skeletal muscle.	2001 May 1	11316577
Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen.	2001 May 11	11335011
6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum.	2001 May 8	11338183

Patents

Sample Use Guides

In Vivo Use Guide

The preferable method of use is to apply Salicylic Acid 6% thoroughly to the affected area and to cover the treated area at night after washing and before retiring. Preferably, the skin should be hydrated for a least five minutes prior to application.

Route of Administration: Topical

In Vitro Use Guide

Salicylic acid inhibited hippuric acid formation in the homogenates obtained from the specimens of human liver with IC50 value 0.19 mM

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:12:43 GMT 2023` Edited by `admin` on `Fri Dec 15 15:12:43 GMT 2023`
Record UNII	O414PZ4LPZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Salicylic acid

Official Name

English

LAMIVUDINE IMPURITY C [EP IMPURITY]

Common Name

English

SALICYLIC ACID [USP-RS]

Common Name

English

2-HYDROXYBENZENECARBOXYLIC ACID

Systematic Name

English

COMPOUND W

Brand Name

English

SALICYLIC ACID [EP IMPURITY]

Common Name

English

SALICYLIC ACID [USP]

Common Name

English

SALICYLIC ACID [JAN]

Common Name

English

SALICYLIC ACID [VANDF]

Common Name

English

SALICYLIC ACID [INCI]

Common Name

English

DR. SCHOLL'S CALLUS REMOVERS

Brand Name

English

SALICYLICUM ACIDUM

Common Name

English

FEMA NO. 3985

Code

English

SALICYLIC ACID [USP MONOGRAPH]

Common Name

English

SALICYLIC ACID [MART.]

Common Name

English

SULFASALAZINE IMPURITY H [EP IMPURITY]

Common Name

English

SALICYLICUM ACIDUM [HPUS]

Common Name

English

SALICYLIC ACID [GREEN BOOK]

Common Name

English

SALICYLIC ACID [MI]

Common Name

English

ACETYLSALICYLIC ACID IMPURITY C [EP IMPURITY]

Common Name

English

SALICYLIC ACID [HSDB]

Common Name

English

NSC-180

Code

English

2-HYDROXYBENZOIC ACID [FHFI]

Common Name

English

CARBASALATE CALCIUM IMPURITY C [EP IMPURITY]

Common Name

English

Salicylic acid [WHO-DD]

Common Name

English

DL-LYSINE ACETYLSALICYLATE IMPURITY A [EP IMPURITY]

Common Name

English

2-HYDROXYBENZOIC ACID

Systematic Name

English

ACIDUM SALICYLICUM [WHO-IP LATIN]

Common Name

English

SALICYLIC ACID [EP MONOGRAPH]

Common Name

English

SALICYLIC ACID [WHO-IP]

Common Name

English

K-557

Code

English

MESALAZINE IMPURITY H [EP IMPURITY]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 358.710

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

CFR

21 CFR 333.310

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

NCI_THESAURUS

C257

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

NCI_THESAURUS

C52588

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

CFR

21 CFR 358.510

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

WHO-VATC

QD01AE12

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

CFR

21 CFR 862.3830

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

EPA PESTICIDE CODE

76602

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

CFR

21 CFR 358.720

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

WHO-VATC

QS01BC08

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

WHO-ATC

S01BC08

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

CFR

21 CFR 358.110

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

FDA ORPHAN DRUG

359211

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

WHO-VATC

QM02AC99

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

JECFA EVALUATION

2-HYDROXYBENZOIC ACID

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

WHO-ATC

D01AE12

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

WHO-ESSENTIAL MEDICINES LIST

13.4

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

Code System Code Type Description

RXCUI

9525

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

PRIMARY

JECFA MONOGRAPH

891

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

HSDB

672

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

FDA UNII

O414PZ4LPZ

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

PUBCHEM

338

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

RXCUI

9522

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

ALTERNATIVE

RS_ITEM_NUM

1609002

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

LACTMED

Salicylic Acid

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

EVMPD

SUB15180MIG

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

WIKIPEDIA

SALICYLIC ACID

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

PRIMARY

CAS

69-72-7

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

WIKIPEDIA

Medical uses of salicylic acid

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

PRIMARY

ECHA (EC/EINECS)

200-712-3

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

MESH

D020156

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

CHEBI

30762

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

IUPHAR

4306

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

NSC

180

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

SMS_ID

100000090038

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

PRIMARY

DRUG CENTRAL

2416

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

CHEBI

16914

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

DAILYMED

O414PZ4LPZ

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

MERCK INDEX

m9739

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

Merck Index

NCI_THESAURUS

C61934

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

WHO INTERNATIONAL PHARMACOPEIA

SALICYLIC ACID

Created by admin on Fri Dec 15 15:12:44 GMT 2023 , Edited by admin on Fri Dec 15 15:12:44 GMT 2023

PRIMARY

Description: Colourless crystals, usually needle-like, or a white, crystalline powder; odourless. Solubility: Slightly soluble in water; soluble in 4 parts of ethanol (~750 g/l) TS and in 3 parts of ether R. Category: Keratolytic. Storage: Salicylic acid should be kept in a well-closed container. Definition: Salicylic acid contains not less than 99.0% and not more than 101.0% of C7H6O3, calculated with reference to the dried substance.

ChEMBL

CHEMBL424

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

DRUG BANK

DB00936

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

EPA CompTox

DTXSID7026368

Created by admin on Fri Dec 15 15:12:43 GMT 2023 , Edited by admin on Fri Dec 15 15:12:43 GMT 2023

PRIMARY

Related Record Type Details


					W49EC1DTLR

MERCURIC SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					078ORG4DXO

SALICYLIC ACID MONOETHANOLAMINE

SALT/SOLVATE -> PARENT

Amount:


					41728CY7UX

MAGNESIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					0T3Q181657

AMMONIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					N5ZZ1LY24G

THEOBROMINE CALCIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					I59XKK41WY

COLCHICINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					6DY04L71DR

QUININE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					96OQ2F972S

ZINC SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					JQ69D454N1

MAGNESIUM SALICYLATE ANHYDROUS

SALT/SOLVATE -> PARENT

Amount:


					2046ZRO9VU

PHYSOSTIGMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					6TC6NN0876

STEVIA REBAUDIUNA LEAF

PARENT -> CONSTITUENT ALWAYS PRESENT

Comments:

Salicylic acid content for water extract of plant callus was 3.22+/-0.06 as expressed as mg/100 g of dry base of extract. For the analysis of phenolic acids, a Nova pack C18 UG120 equipped with a Guard column, a JASCO HPLC system consisting of a column oven, a UV-Vis diode array detector set at 280 nm, a Liquid chromatography pump and a ChromNAV software program were used.

Amount:


					B2F298X1AJ

DEXTROMETHORPHAN SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					H8O4040BHD

TROLAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					Q1Y52JQ86J

CINCHONIDINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					65A568ZIJ4

DEQUALINIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					APY0XA4O95

BENZYDAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					KD510K1IQW

CHOLINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					DJJ95FJP1H

CHOLINE MAGNESIUM TRISALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					4JVD4X01MJ

IMIDAZOLE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					GYG64DIH9P

MENYANTHES TRIFOLIATA LEAF

PARENT -> CONSTITUENT ALWAYS PRESENT

Amount:


					X43D4L3DQC

IRIS VERSICOLOR ROOT

PARENT -> CONSTITUENT ALWAYS PRESENT

Amount:


					TW371I5GLO

SALCOLEX

SALT/SOLVATE -> PARENT

Amount:


					K6CH6HC2O8

BISMUTH TRISALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					CSU8L38K2O

CADMIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					5RZJ5HAM62

PHENYLMERCURY SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					129S234L64

ZINC BORODISALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					K91YT16P5M

POTASSIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					62TEY51RR1

BISMUTH SUBSALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					5V7PT38BJU

DIETHYLAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					7UP781YBR6

SALCOLEX ANHYDROUS

SALT/SOLVATE -> PARENT

Amount:


					93F1SP6QIN

LITHIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					U7R78VQQ6O

CAFFEINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					098DXT30J6

DODECYLAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					F558OJK9JG

ANTIPYRINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR


					Z1EQ13H492

SALICYLATE MEGLUMINE

SALT/SOLVATE -> PARENT

Amount:


					5CZ96E2J60

HYDROXYALUMINUM DISALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					080UKX74TN

DIMETHOCAINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					O42S49LAA4

THEOBROMINE SODIUM SALICYLATE ANHYDROUS

SALT/SOLVATE -> PARENT

Amount:


					744Q1CL77H

NICOTINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					AF3Z6434KS

EDASALONEXENT

DERIVATIVE -> PARENT

Amount:


					F83ZXV3W0G

TRIETHYLAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					2J53IGE6Y9

ETHYLAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					P6VR6P4A5V

THEOBROMINE SODIUM SALICYLATE MONOHYDRATE

SALT/SOLVATE -> PARENT

Amount:


					OGF9EV99TC

STRONTIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					VWZ980637N

THEOPHYLLINE CALCIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					707L3YC54L

DIPHENHYDRAMINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					DRF395F9AY

BETAINE SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					0001H6R5H1

CEROUS SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					Z4B6561488

GALIUM APARINE WHOLE

PARENT -> CONSTITUENT ALWAYS PRESENT

Amount:


					WIQ1H85SYP

SODIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:


					0841QCS0DK

CALCIUM SALICYLATE

SALT/SOLVATE -> PARENT

Amount:

Related Record Type Details


					T4S4WQP2BH

MONOMETHYLTRISILANOL SALICYLATE

PRODRUG -> METABOLITE ACTIVE

Amount:


					R16CO5Y76E

ASPIRIN

PARENT -> METABOLITE ACTIVE

Interaction Type:

MINOR

Qualification:

URINE

Amount:

Related Record Type Details


					R16CO5Y76E

ASPIRIN

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					7IS9N8KPMG

SULFATE ION

IMPURITY -> PARENT

Qualification:

EP

Amount:


					EM8BM710ZC

SALICYLAMIDE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					Q32ZN48698

CHLORIDE ION

IMPURITY -> PARENT

Qualification:

EP

Amount:


					339NCG44TV

Phenol

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

Ph.Eur.; USP

Amount:


					7IS9N8KPMG

SULFATE ION

IMPURITY -> PARENT

Qualification:

INTERNATIONAL PHARMACOPEIA

Amount:


					P87FF77O00

4-HYDROXYISOPHTHALIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					3XC8GUZ6CB

SULFASALAZINE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					Q32ZN48698

CHLORIDE ION

IMPURITY -> PARENT

Qualification:

INTERNATIONAL PHARMACOPEIA

Amount:


					Q32ZN48698

CHLORIDE ION

IMPURITY -> PARENT

Qualification:

USP

Amount:


					2T8Q726O95

LAMIVUDINE

PARENT -> IMPURITY

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					7IS9N8KPMG

SULFATE ION

IMPURITY -> PARENT

Qualification:

USP

Amount:


					N667F17JP1

CARBASPIRIN CALCIUM

PARENT -> IMPURITY

Amount:


					JG8Z55Y12H

4-HYDROXYBENZOIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					4Q81I59GXC

MESALAMINE

PARENT -> IMPURITY

Comments:

Correction factors: for the calculation of contents, multiply the peak areas by 1.4

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					2JJ274J145

ASPIRIN DL-LYSINE

PARENT -> IMPURITY

Amount:

Related Record Type Details


					O414PZ4LPZ

Salicylic acid

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdfCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00936https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022029s003lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/salicylic-acid.html

T_1/2

Drug as perpetrator